Get the Stockscreener App
1.57
6.08%
0.09
Milestone Pharmaceuticals Inc stock is traded at $1.57, with a volume of 567.78K.
It is up +6.08% in the last 24 hours and up +4.67% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.48
Open:
$1.49
24h Volume:
567.78K
Relative Volume:
3.66
Market Cap:
$86.56M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.146
EPS:
-1.37
Net Cash Flow:
$-46.54M
1W Performance:
+9.79%
1M Performance:
+4.67%
6M Performance:
-7.10%
1Y Performance:
-44.13%
1-Day Range:
$1.47
$1.65
1-Week Range:
$1.40
$1.65
52-Week Range:
$1.12
$3.52
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Head to Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Alkermes (NASDAQ:ALKS) - Defense World
InnoCare Pharma (SEHK:9969) Achieves Key Milestone with ICP-488 Phase II Success in Psoriasis Treatment - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies - Marketscreener.com
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Yahoo Finance
MSD acquires cancer therapeutics developer Modifi Biosciences - Pharmaceutical Technology
Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Wainwright maintains Buy rating on Milestone Pharma stock By Investing.com - Investing.com UK
Millennium Management LLC Sells 105,682 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46% - Yahoo Finance
OKUR stock soars to all-time high, reaching $20 milestone - Investing.com
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MyChesCo
1 AI Biotech Stock That Just Scored a Major Milestone - TradingView
Antiarrhythmic Drugs Market Size And Share Report, 2030 - Grand View Research
Scientech Research LLC Invests $289,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Susquehanna Fundamental Investments LLC Makes New Investment in Boston Scientific Co. (NYSE:BSX) - Defense World
MP Materials (NYSE:MP) PT Raised to $23.00 - Defense World
ProShare Advisors LLC Raises Stock Holdings in Bruker Co. (NASDAQ:BRKR) - Defense World
Toronto Dominion Bank Has $2.66 Million Position in Veeva Systems Inc. (NYSE:VEEV) - Defense World
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Large Increase in Short Interest - MarketBeat
NRX-100 (Ketamine) Reaches Stability Milestone - Contract Pharma
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) - StockTitan
Milestone Pharmaceuticals to Host Investor KOL Event - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 0.7% - MarketBeat
Delaware Court of Chancery Finds Buyer Failed to Use Commercially Reasonable Efforts in Pharma Milestone Payment Case - The Harvard Law School Forum on Corporate Governance
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease - StockTitan
Citius Pharmaceuticals defers FDA milestone payment - Investing.com
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Scilex Holding (NASDAQ:SCLX) Stock Quotes, Forecast and News Summary - Benzinga
TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of $441M - Investing.com
Hemogenyx Pharmaceuticals passes crucial milestone ahead of phase I trial - Proactive Investors UK
Etripamil nasal spray shows promise in China trial By Investing.com - Investing.com Australia
Etripamil nasal spray shows promise in China trial - Investing.com
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China - GlobeNewswire Inc.
Milestone Pharmaceuticals welcomes new board member Joseph Papa - Investing.com
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration - Business Wire
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 - Yahoo Finance
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Yahoo Finance
Warren Buffett's Berkshire Hathaway Breaks $1 Trillion: Poll Suggests Big Pharma, Not Tech, Is Next Contender - Benzinga
Brokers Offer Predictions for Milestone Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:MIST) - MarketBeat
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024 - StockTitan
HC Wainwright Analysts Lower Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Given “Buy” Rating at HC Wainwright - Defense World
Rodman & Renshaw Initiates Coverage of Milestone Pharmaceuticals (MIST) with Buy Recommendation - MSN
HC Wainwright Reaffirms "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from Analysts at Rodman & Renshaw - MarketBeat
Milestone stock wins Buy at Rodman Renshaw (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Rodman & Renshaw - Defense World
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):